Ray CRO
↗Cairo, Egypt
Ray CRO is a regional full-service Contract Research Organization (CRO) established in February 2010. Headquartered in Cairo, Egypt, the company provides comprehensive clinical research support to the pharmaceutical, biotechnology, and medical device industries. They specialize in managing international clinical trials, real-world evidence (RWE) studies, and health economic evaluations across the Middle East and North Africa (MENA) region.
The company offers a wide range of services including clinical operations (Phase II-IV), regulatory affairs, pharmacovigilance, medical writing, and data management. Ray CRO is known for its deep expertise in navigating the complex regulatory landscapes of Egypt, Saudi Arabia, and the UAE, and has managed over 300 clinical projects to date.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$5M-$10M
Founded:2010
Ownership:private
Status:operating
FUNDING
Stage:Late Stage / Private
PIPELINE
Stage:Commercial
Lead Drug Stage:Phase 4
Modalities:Small molecule, Biologics, Medical Devices
Active Trials:45
Trial Phases:Phase 1: 2 | Phase 2: 12 | Phase 3: 20 | Phase 4: 11
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:RAY-PSP (Patient Support Programs), Dataclin, Zi-Diligence
Key Partnerships:Sanofi (Clinical trial management and RWE studies), Pfizer (Regulatory and clinical operations support), Astellas Pharma
COMPETITION
Position:Leader
Competitors:ClinServ International, MCT CRO, IQVIA (Regional MENA offices), PPD, Clinart-MENA
LEADERSHIP
Key Executives:
Dr. Mosaad Morsi - Chairman and CEO
Scientific Founders:Dr. Mosaad Morsi
LINKS
Website:ray-cro.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Ray CRO. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.